Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

NCT ID: NCT05872867

Last Updated: 2024-03-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-14
• Study Completion Date: 2026-02-22

Brief Summary

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).

Conditions

Advanced Solid Tumor; Metastatic Solid Tumor; Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer; Non Small Cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose escalation (Stage 1)

WM-A1-3389 administered intravenously, weekly for 21 days of each cycle

Group Type: EXPERIMENTAL

WM-A1-3389

Intervention Type: BIOLOGICAL

Anti-IGSF1 (Immunoglobulin superfamily member 1)

Dose escalation (Stage 2)

WM-A1-3389 administered intravenously, weekly for 21 days of each cycle Pembrolizumab 200 mg administered intravenously, every 3 weeks for 21 days of each cycle

Group Type: EXPERIMENTAL

WM-A1-3389

Intervention Type: BIOLOGICAL

Anti-IGSF1 (Immunoglobulin superfamily member 1)

Pembrolizumab

Intervention Type: BIOLOGICAL

Anti-PD-1(Programmed cell death protein 1)

Interventions

WM-A1-3389

Anti-IGSF1 (Immunoglobulin superfamily member 1)

Intervention Type: BIOLOGICAL

Pembrolizumab

Anti-PD-1(Programmed cell death protein 1)

Intervention Type: BIOLOGICAL

Other Intervention Names

KEYTRUDA®

Eligibility Criteria

Inclusion Criteria

[Stage 1: monotherapy]

1. Be ≥19 and <75 years of age

2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable advanced or metastatic solid tumors that have been confirmed as progressed disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility

3. IGSF1 positive expression

4. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Have life expectancy ≥ 12 weeks

7. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening phase, one re-test will be permitted):

1. Absolute neutrophil count (ANC) ≥ 1,500/mm3

2. Platelet count ≥ 100,000/mm3

3. Hemoglobin (Hb) ≥ 9 g/dL

4. Total bilirubin ≤ 1.5 X Institutional Upper Limit of Normal (IULN) (Not applicable to patients with Gilbert syndrome)

5. Serum creatinine ≤ 1.5 X IULN

6. Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) ≤ 2.5 X IULN (AST and ALT ≤ 5 X IULN in patients with confirmed liver metastasis)

7. Prothrombin time (PT) ≤ 1.5 X IULN *IULN: Institutional Upper Limit of Normal

8. Have provided archival tumor tissue sample obtained within 3 months prior to IP administration or newly obtained biopsy

9. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration

10. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial

[Stage 2: Combination therapy]

1. Be ≥ 19 and < 75 years of age

2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable advanced or metastatic NSCLC

1. Have been confirmed as progressive disease after standard of care or for which no further standard therapy is available due to intolerance or incompatibility

2. Have been confirmed as progressive disease during or after anti-cancer therapy including programmed cell death protein 1 (PD-1) inhibitors and programmed cell death-Ligand 1 (PD-L1) inhibitors

3. IGSF1 positive expression

4. PD-L1 low or negative expression (tumor proportion score [TPS] < 50%)

3. Have measurable disease defined as at least one lesion based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

4. Have ECOG performance status score of 0 or 1

5. Have life expectancy ≥ 12 weeks

6. Have adequate organ functions defined as the following laboratory test criteria at screening (During the screening period, one re-test will be permitted):

1. Absolute neutrophil count (ANC) ≥ 1500/mm3

2. Platelet count ≥ 100,000/mm3

3. Hemoglobin (Hb) ≥ 9 g/dL

4. Total bilirubin ≤ 1.5 X IULN (Not applicable to patients with Gilbert's syndrome)

5. Serum creatinine ≤ 1.5 X IULN

6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 2.5 X IULN (AST and ALT ≤ 5 X IULN in patients with confirmed liver metastasis)

7. Prothrombin time (PT) ≤ 1.5 X IULN *IULN: Institutional Upper Limit of Normal

7. Have provided archival tumor sample obtained within 3 months prior to IP administration or newly obtained biopsy prior to IP administration

8. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration

9. Participant (or legally acceptable representative if applicable) provides written infromed consent for the trial

Exclusion Criteria

[Common]

1. Have experienced hypersensitivity to IP, any of its excipients or other monoclonal antibody

2. Have any of the following documented medical history or surgical/procedure history:

1. Other primary malignant tumor (subject may be enrolled if they have neither received any treatment nor experienced disease progression within 3 years) or hematologic malignancy

2. Major surgery within 4 weeks or minor surgery within 2 weeks prior to IP administration

3. Clinically significant arrhythmia, acute myocardial infarction, unstable angina pectoris, or New York Heart Association (NYHA) class Ⅲ or Ⅳ heart failure within 6 months prior to IP administration

4. Severe cerebrovascular disease within 6 months prior to IP administration

5. Pulmonary thrombosis, deep vein thrombosis, bronchial asthma, obstructive pulmonary disease, or other severe or life-threatening lung diseases (e.g., acute respiratory distress syndrome, lung failure) considered to be inappropriate for study participationt, within 6 months prior to IP administration

6. Pneumonia or interstitial lung disease requiring steroids

f. Infection requiring systemic antibiotics or antiviral agents, etc. or uncontorlled Grade ≥ 3 active infectious diseases within 2 weeks prior to IP administration g. Risk factors of ileus or intestinal perforation (including but not limited to history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis) h. Auto-immune diseases

3. Have any of the following diseases:

1. Central nervous system or brain metastasis that is uncontrolled or with clinically significant symptoms (except for patients who stopped systemic corticosteroids at least 4 weeks before IP administration and have been stable for at least 4 weeks)

2. Abnormal ECG regarded as clinically significant by the investigator

3. Uncontrolled hypertension (systolic blood pressure [SBP] > 160 mmHg or diastolic blood pressure [DBP] > 100 mmHg)

4. Active infection requiring treatment

5. Active hepatitis B or C virus infection

6. History of human immunodeficiency virus infection (HIV) infection

7. Symptomatic ascites or pleural effusion (except for patients who were treated and clinically stable)

8. Diseases that may affect the study results based on the judgement of the investigator

4. Have any of the following medication or treatment history:

1. Anticancer therapy (chemotherapy, hormonal therapy, targeted therapy, or radiotherapy) within 4 weeks prior to IP administration

2. Immunotherapy such as anti-PD-1, anti PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), etc. within 4 weeks prior to IP administration

3. Treatment with live attenuated vaccine within 4 weeks prior to IP administration

4. Treatment with drugs classified as Immunosuppressants, immunomodulators, or immunocytokines within 1 week prior to IP administration (Immunosuppressants, topical corticosteroids, prednisolone 10 mg/day or ≤ equivalent dose of systemic corticosteroids may be permitted for the treatment or prevention of AEs.)

5. Allogeneic bone marrow or solid organ transplantation

5. Pregnant women, lactating women or men/women of child-bearing potential who are unwilling to maintain abstinence or use adequate methods of contraception or do not consent to refrain from donation of sperm/ova for at least 6 months after the last IP administration

• Adequate methods of contraception

1. Oral or injectable hormonal therapy

2. Implantation of intrauterine device or intrauterine system

3. Surgical sterilization (vasectomy, tubal ligation, etc.)

6. Have received any other IP or implantation of investigational medical device within 4 weeks prior to IP administration in the present study

7. Patients who are considered ineligible or unable to participate in the study for other reasons based on the judgement of the investigator

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Wellmarker Bio

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Seoul St. Mary's Hospital

Seoul, Seocho-gu, South Korea

Site Status: RECRUITING

Incheon St. Mary's Hospital

Incheon, Yeonsu-gu, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Wellmarker BIO

Role: CONTACT

selee@wmbio.co

+82-2-6933-5667

Other Identifiers

MK-3475-E90

Identifier Type: OTHER

Identifier Source: secondary_id

KEYNOTE-E90

Identifier Type: OTHER

Identifier Source: secondary_id

WMA13389-101

Identifier Type: -

Identifier Source: org_study_id